ArticleClinical hypertension2025
Cardiometabolic risk factors and hypertension progression in women according to the 2017 ACC/AHA guideline for the detection of high blood pressure: a multi-state modeling approach.
Article in Clinical hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite extensive research on blood pressure (BP) progression, the impact of cardiometabolic risk factors on different stages of hypertension (HTN) remains poorly understood. This study aimed to investigate how these factors affect HTN progression. Methods: A community-based study of 1,740 women aged > 20 years was followed from 1999 to 2019. A multi-state model with six transitions was employed to analyze the data. Results: Our findings revealed that the hazard of transition from normal BP to elevated BP intensified by age (hazard ratio [HR], 1.06; 95% confidence interval [CI], 1.04-1.08), body mass index (BMI) (HR, 1.07; 95% CI, 1.04-1.09), and a family history of HTN (HR, 2.65; 95% CI, 1.27-5.38). In addition, age (HR, 1.04; 95% CI, 1.01-1.06), BMI (HR, 1.03; 95% CI, 1.01-1.07), and parity (HR, 0.87; 95% CI, 0.77-0.97) were significantly associated with the hazard of transition from normal BP to HTN stage 1. BMI was the only risk factor in the transition from normal BP to HTN stage 2 (HR, 1.12; 95% CI, 1.01-1.24). Moreover, the family history of HTN (HR, 3.01; 95% CI, 1.02-6.83) and the type 2 diabetes mellitus (T2DM) (HR, 3.98; 95% CI, 1.81-7.73) were strongly related to the transition risk from elevated BP to HTN stage 1. Furthermore, T2DM (HR, 3.21; 95% CI, 1.11-7.26) and menopausal status (HR, 3.33; 95% CI, 1.11-7.95) were significantly associated with an increased risk of progression from HTN stage 1 to HTN stage 2. Conclusions: This study demonstrates that age, BMI, and family history of HTN are key risk factors for the initial progression of HTN in women with normal BP, whereas T2DM and menopausal status play a more critical in the progression to higher stages of HTN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.